Methods of making chimeric antigen receptor - expressing cells
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsFelipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng
Life of this patent
Estimating the term…
Abstract
The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
Claims28
A method of making a population of immune effector cells that is depleted of T regulatory cells and can be engineered to express a chimeric antigen receptor (CAR), the method comprising:
- providing a population of immune effector cells;
- and
- removing T regulatory cells from the population,
- to thereby provide a population of T regulatory-depleted cells, suitable for expression of a CAR.
(canceled)
(canceled)
8-10. (canceled)
(canceled)
16-26. (canceled)
A method of making a population of chimeric antigen receptor (CAR)-expressing immune effector cells, the method comprising:
- (a) providing a population of immune effector cells, wherein a plurality of the immune effector cells in the population comprises a nucleic acid encoding a CAR;
- and
- (b) contacting the population of immune effector cells with an interleukin-15 (IL-15);
- an interleukin-7 (IL-7);
- or a combination of IL-15 and IL-7.
(canceled)
36-46. (canceled)
A method of making a population of chimeric antigen receptor (CAR)-expressing immune effector cells, the method comprising:
- (a) providing a population of cells comprising immune effector cells from an apheresis sample from a patient with chronic lymphocytic leukemia;
- (b) depleting CD25-expressing cells from the population of cells of step (a) to provide a population of CD25-depleted cells, wherein the population of CD25-depleted cells is a population that contains less than 50% CD25+ cells in the population of cells of step (a) when assessed by flow cytometry;
- (c) contacting the CD25-depleted cells with anti-CD3 and anti-CD28 coated beads;
- and
- (d) transducing the population of CD25-depleted cells with a lentivirus vector encoding a chimeric antigen receptor;
- to thereby provide a population of CAR-expressing immune effector cells.
Dependencies are inferred from the claim text.